{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "", "original": "By REUTERS", "person": [], "organization": "REUTERS"}, "abstract": "Food and Drug Administration approves Eli Lilly drug Portrazza to treat patients with advanced squamous non-small cell lung cancer.", "type_of_material": "Brief", "word_count": "92", "lead_paragraph": "The agency approved Portrazza, in combination with two forms of chemotherapy, to treat advanced squamous nonsmall cell lung cancer, the most common type.", "pub_date": "2015-11-25T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Approves Eli Lilly Drug for Advanced Lung Cancer", "content_kicker": "Business Briefing", "print_headline": "F.D.A. Approves Eli Lilly Drug for Advanced Lung Cancer"}, "snippet": "The agency approved Portrazza, in combination with two forms of chemotherapy, to treat advanced squamous nonsmall cell lung cancer, the most common type.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/11/25/business/fda-approves-eli-lilly-drug-for-advanced-lung-cancer.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Lung Cancer", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Eli Lilly and Company", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "5654f6b638f0d80209d5aedd", "source": "The New York Times"}